Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57


Factor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising "Hot-Spot" Lysine Residues.

van den Biggelaar M, Madsen JJ, Faber JH, Zuurveld MG, van der Zwaan C, Olsen OH, Stennicke HR, Mertens K, Meijer AB.

J Biol Chem. 2015 Jul 3;290(27):16463-76. doi: 10.1074/jbc.M115.650911. Epub 2015 Apr 21.


Evidence for restricted reactivity of ADAMDEC1 with protein substrates and endogenous inhibitors.

Lund J, Troeberg L, Kjeldal H, Olsen OH, Nagase H, Sørensen ES, Stennicke HR, Petersen HH, Overgaard MT.

J Biol Chem. 2015 Mar 6;290(10):6620-9. doi: 10.1074/jbc.M114.601724. Epub 2015 Jan 6.


Biochemical and structural characterization of SplD protease from Staphylococcus aureus.

Zdzalik M, Kalinska M, Wysocka M, Stec-Niemczyk J, Cichon P, Stach N, Gruba N, Stennicke HR, Jabaiah A, Markiewicz M, Kedracka-Krok S, Wladyka B, Daugherty PS, Lesner A, Rolka K, Dubin A, Potempa J, Dubin G.

PLoS One. 2013 Oct 9;8(10):e76812. doi: 10.1371/journal.pone.0076812. eCollection 2013.


Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.

Bloem E, van den Biggelaar M, Wroblewska A, Voorberg J, Faber JH, Kjalke M, Stennicke HR, Mertens K, Meijer AB.

J Biol Chem. 2013 Oct 11;288(41):29670-9. doi: 10.1074/jbc.M113.473116. Epub 2013 Sep 5.


ADAMDEC1 is a metzincin metalloprotease with dampened proteolytic activity.

Lund J, Olsen OH, Sørensen ES, Stennicke HR, Petersen HH, Overgaard MT.

J Biol Chem. 2013 Jul 19;288(29):21367-75. doi: 10.1074/jbc.M113.474536. Epub 2013 Jun 10.


A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.

Stennicke HR, Kjalke M, Karpf DM, Balling KW, Johansen PB, Elm T, Øvlisen K, Möller F, Holmberg HL, Gudme CN, Persson E, Hilden I, Pelzer H, Rahbek-Nielsen H, Jespersgaard C, Bogsnes A, Pedersen AA, Kristensen AK, Peschke B, Kappers W, Rode F, Thim L, Tranholm M, Ezban M, Olsen EH, Bjørn SE.

Blood. 2013 Mar 14;121(11):2108-16. doi: 10.1182/blood-2012-01-407494. Epub 2013 Jan 18.


Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.

Agersø H, Stennicke HR, Pelzer H, Olsen EN, Merricks EP, Defriess NA, Nichols TC, Ezban M.

Haemophilia. 2012 Nov;18(6):941-7. doi: 10.1111/j.1365-2516.2012.02896.x. Epub 2012 Jul 20.


Periodontal pathogens affect the level of protease inhibitors in gingival crevicular fluid.

Laugisch O, Schacht M, Guentsch A, Kantyka T, Sroka A, Stennicke HR, Pfister W, Sculean A, Potempa J, Eick S.

Mol Oral Microbiol. 2012 Feb;27(1):45-56. doi: 10.1111/j.2041-1014.2011.00631.x. Epub 2011 Dec 7.


Inhibition of Staphylococcus aureus cysteine proteases by human serpin potentially limits staphylococcal virulence.

Kantyka T, Plaza K, Koziel J, Florczyk D, Stennicke HR, Thogersen IB, Enghild JJ, Silverman GA, Pak SC, Potempa J.

Biol Chem. 2011 May;392(5):483-9. doi: 10.1515/BC.2011.044.


Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa.

Karpf DM, Sørensen BB, Hermit MB, Holmberg HL, Tranholm M, Bysted BV, Groth AV, Bjørn SE, Stennicke HR.

Thromb Res. 2011 Aug;128(2):191-5. doi: 10.1016/j.thromres.2011.02.018. Epub 2011 Mar 22.


Characterization of canine coagulation factor VII and its complex formation with tissue factor: canine-human cross-species compatibility.

Knudsen T, Kristensen AT, Sørensen BB, Olsen OH, Stennicke HR, Petersen LC.

J Thromb Haemost. 2010 Aug;8(8):1763-72. doi: 10.1111/j.1538-7836.2010.03931.x. Epub 2010 May 27.


Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma.

Johansen PB, Bjørn SE, Agersø H, Thorup I, Hermit MB, Sørensen B, Stennicke HR, Ezban M, Tranholm M.

Thromb Haemost. 2010 Jul;104(1):157-64. doi: 10.1160/TH09-11-0797. Epub 2010 Apr 13.


Coagulation factor XIII variants with altered thrombin activation rates.

Andersen MD, Kjalke M, Bang S, Lautrup-Larsen I, Becker P, Andersen AS, Olsen OH, Stennicke HR.

Biol Chem. 2009 Dec;390(12):1279-83. doi: 10.1515/BC.2009.142.


Structural and functional characterization of SplA, an exclusively specific protease of Staphylococcus aureus.

Stec-Niemczyk J, Pustelny K, Kisielewska M, Bista M, Boulware KT, Stennicke HR, Thogersen IB, Daugherty PS, Enghild JJ, Baczynski K, Popowicz GM, Dubin A, Potempa J, Dubin G.

Biochem J. 2009 May 1;419(3):555-64. doi: 10.1042/BJ20081351.


Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives.

Stennicke HR, Ostergaard H, Bayer RJ, Kalo MS, Kinealy K, Holm PK, Sørensen BB, Zopf D, Bjørn SE.

Thromb Haemost. 2008 Nov;100(5):920-8.


Enzymatic activity of the Staphylococcus aureus SplB serine protease is induced by substrates containing the sequence Trp-Glu-Leu-Gln.

Dubin G, Stec-Niemczyk J, Kisielewska M, Pustelny K, Popowicz GM, Bista M, Kantyka T, Boulware KT, Stennicke HR, Czarna A, Phopaisarn M, Daugherty PS, Thøgersen IB, Enghild JJ, Thornberry N, Dubin A, Potempa J.

J Mol Biol. 2008 May 30;379(2):343-56. doi: 10.1016/j.jmb.2008.03.059. Epub 2008 Apr 3.


The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry.

Rand KD, Andersen MD, Olsen OH, Jørgensen TJ, Ostergaard H, Jensen ON, Stennicke HR, Persson E.

J Biol Chem. 2008 May 9;283(19):13378-87. doi: 10.1074/jbc.M709716200. Epub 2008 Mar 14.


Activation mechanism and substrate specificity of the Drosophila initiator caspase DRONC.

Snipas SJ, Drag M, Stennicke HR, Salvesen GS.

Cell Death Differ. 2008 May;15(5):938-45. doi: 10.1038/cdd.2008.23. Epub 2008 Feb 29.


Engineering the substrate and inhibitor specificities of human coagulation Factor VIIa.

Larsen KS, Østergaard H, Bjelke JR, Olsen OH, Rasmussen HB, Christensen L, Kragelund BB, Stennicke HR.

Biochem J. 2007 Aug 1;405(3):429-38.


Allosteric activation of coagulation factor VIIa visualized by hydrogen exchange.

Rand KD, Jørgensen TJ, Olsen OH, Persson E, Jensen ON, Stennicke HR, Andersen MD.

J Biol Chem. 2006 Aug 11;281(32):23018-24. Epub 2006 May 10.


Chemical ligation--an unusual paradigm in protease inhibition.

Stennicke HR, Salvesen GS.

Mol Cell. 2006 Mar 17;21(6):727-8. Review.


Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study.

Petersen LC, Nørby PL, Branner S, Sørensen BB, Elm T, Stennicke HR, Persson E, Bjørn SE.

Thromb Res. 2005;116(1):75-85. Epub 2004 Dec 7.


Characteristics of the caspase-like catalytic domain of human paracaspase.

Snipas SJ, Wildfang E, Nazif T, Christensen L, Boatright KM, Bogyo M, Stennicke HR, Salvesen GS.

Biol Chem. 2004 Nov;385(11):1093-8.


Early processing of Bid and caspase-6, -8, -10, -14 in the canine brain during cardiac arrest and resuscitation.

Krajewska M, Rosenthal RE, Mikolajczyk J, Stennicke HR, Wiesenthal T, Mai J, Naito M, Salvesen GS, Reed JC, Fiskum G, Krajewski S.

Exp Neurol. 2004 Oct;189(2):261-79.


Sequential autolytic processing activates the zymogen of Arg-gingipain.

Mikolajczyk J, Boatright KM, Stennicke HR, Nazif T, Potempa J, Bogyo M, Salvesen GS.

J Biol Chem. 2003 Mar 21;278(12):10458-64. Epub 2003 Jan 17.


Caspases--at the cutting edge of cell death.

Stennicke HR.

Symp Soc Exp Biol. 2000;52:13-29. Review. No abstract available.


Inhibitor specificity of recombinant and endogenous caspase-9.

Ryan CA, Stennicke HR, Nava VE, Burch JB, Hardwick JM, Salvesen GS.

Biochem J. 2002 Sep 1;366(Pt 2):595-601.


Reprieval from execution: the molecular basis of caspase inhibition.

Stennicke HR, Ryan CA, Salvesen GS.

Trends Biochem Sci. 2002 Feb;27(2):94-101. Review.


Dimer formation drives the activation of the cell death protease caspase 9.

Renatus M, Stennicke HR, Scott FL, Liddington RC, Salvesen GS.

Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14250-5.


Inhibition of distant caspase homologues by natural caspase inhibitors.

Snipas SJ, Stennicke HR, Riedl S, Potempa J, Travis J, Barrett AJ, Salvesen GS.

Biochem J. 2001 Jul 15;357(Pt 2):575-80.


Cloning and characterization of an inhibitor of apoptosis protein (IAP) from Bombyx mori.

Huang Q, Deveraux QL, Maeda S, Stennicke HR, Hammock BD, Reed JC.

Biochim Biophys Acta. 2001 Jan 15;1499(3):191-8.


TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor-alpha-induced apoptosis.

Leo E, Deveraux QL, Buchholtz C, Welsh K, Matsuzawa S, Stennicke HR, Salvesen GS, Reed JC.

J Biol Chem. 2001 Mar 16;276(11):8087-93. Epub 2000 Nov 29.


ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas.

Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM.

Curr Biol. 2000 Nov 2;10(21):1359-66.


Caspase assays.

Stennicke HR, Salvesen GS.

Methods Enzymol. 2000;322:91-100. No abstract available.


Crystal structure of the apoptotic suppressor CrmA in its cleaved form.

Renatus M, Zhou Q, Stennicke HR, Snipas SJ, Turk D, Bankston LA, Liddington RC, Salvesen GS.

Structure. 2000 Jul 15;8(7):789-97.


Caspases - controlling intracellular signals by protease zymogen activation.

Stennicke HR, Salvesen GS.

Biochim Biophys Acta. 2000 Mar 7;1477(1-2):299-306. Review.


Evolutionary conservation of apoptosis mechanisms: lepidopteran and baculoviral inhibitor of apoptosis proteins are inhibitors of mammalian caspase-9.

Huang Q, Deveraux QL, Maeda S, Salvesen GS, Stennicke HR, Hammock BD, Reed JC.

Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1427-32.


Endogenous inhibitors of caspases.

Deveraux QL, Stennicke HR, Salvesen GS, Reed JC.

J Clin Immunol. 1999 Nov;19(6):388-98. Review.


Catalytic properties of the caspases.

Stennicke HR, Salvesen GS.

Cell Death Differ. 1999 Nov;6(11):1054-9. Review.


Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases.

Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC.

EMBO J. 1999 Oct 1;18(19):5242-51.


Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation.

Wolf BB, Goldstein JC, Stennicke HR, Beere H, Amarante-Mendes GP, Salvesen GS, Green DR.

Blood. 1999 Sep 1;94(5):1683-92.


Caspases: preparation and characterization.

Stennicke HR, Salvesen GS.

Methods. 1999 Apr;17(4):313-9.


Caspase-9 can be activated without proteolytic processing.

Stennicke HR, Deveraux QL, Humke EW, Reed JC, Dixit VM, Salvesen GS.

J Biol Chem. 1999 Mar 26;274(13):8359-62.


Granzyme B mimics apical caspases. Description of a unified pathway for trans-activation of executioner caspase-3 and -7.

Yang X, Stennicke HR, Wang B, Green DR, Jänicke RU, Srinivasan A, Seth P, Salvesen GS, Froelich CJ.

J Biol Chem. 1998 Dec 18;273(51):34278-83.


Regulation of cell death protease caspase-9 by phosphorylation.

Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC.

Science. 1998 Nov 13;282(5392):1318-21.


Pro-caspase-3 is a major physiologic target of caspase-8.

Stennicke HR, Jürgensmeier JM, Shin H, Deveraux Q, Wolf BB, Yang X, Zhou Q, Ellerby HM, Ellerby LM, Bredesen D, Green DR, Reed JC, Froelich CJ, Salvesen GS.

J Biol Chem. 1998 Oct 16;273(42):27084-90.


Properties of the caspases.

Stennicke HR, Salvesen GS.

Biochim Biophys Acta. 1998 Sep 8;1387(1-2):17-31. Review.


IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases.

Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC.

EMBO J. 1998 Apr 15;17(8):2215-23.


Reversed-flow affinity elution applied to the purification of carboxypeptidase Y.

Mortensen UH, Stennicke HR, Breddam K.

Anal Biochem. 1998 May 1;258(2):236-9.


Supplemental Content

Loading ...
Support Center